Article

Common Rheumatoid Arthritis Drug Effective in Treating Rare Eye Disease

Adalimumab also found to be effective in treating non-infectious uveitis.

The commonly used medication for rheumatoid arthritis, adalimumab, was found to be effective in treating non-infectious uveitis during a recent study.

Uveitis is a rare eye disease that affects up to 5 in 10,000 individuals. Non-anterior, non-infectious uveitis affects approximately 40% of sufferers, according to a study published in the New England Journal of Medicine.

“We were able to prospectively demonstrate for the very first time that non-infectious uveitis can also be successfully treated with a cortisol-free medication, that will significantly improve the management of uveitis patients who have only partially responded to corticosteroids,” said researcher Talin Barisani-Asenbauer.

Although inflammation typically affects the inner eye, it can also affect other parts of the eye, such as the retina and the vitreous body. Initial symptoms include floaters in the visual field, blurred vision, visual disturbances, and photosensitivity.

Potential complications of uveitis included glaucoma, cataracts, loss of vision, or macular oedema.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit: AwieDarwis | stock.adobe.com
Image credit: viperagp | stock.adobe.com
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com